LOBE SCIENCES LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.015 CAD | 0.00% |
|
-25.00% | -40.00% |
| Feb. 15 | Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023 | CI |
| 2023 | Lobe Sciences Provides Update on L-130 Clinical Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing patient-friendly, practical psychedelic medicines. The Company, through collaborations with partners, is engaged in drug research and development using sub-hallucinatory doses of proprietary compounds to treat Orphan diseases. Its new chemical entities, L-130 and L-131, are being developed to address unmet medical needs such as Chronic Cluster Headaches and other Orphan diseases. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd. and Altemia & Company, LLC.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q2 2024 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.00% | 1.8M | |
| +35.52% | 5.95B | |
| -14.82% | 4.54B | |
| -8.17% | 3.21B | |
| -1.66% | 3.01B | |
| -2.70% | 2.53B | |
| +34.83% | 1.8B | |
| -11.67% | 1.61B | |
| -6.18% | 1.55B | |
| -12.74% | 1.54B |
- Stock Market
- Equities
- LOBE Stock
- News Lobe Sciences Ltd.
- Lobe Sciences : Up 7.7% after Reporting Purchase of Vitamind Line of Wellness Products
